Molecular Formula | C11H6BrCl2NO3S2 |
Molar Mass | 415.11 |
Density | 1.812 |
pKa | 3.45±0.10(Predicted) |
Storage Condition | -20℃ |
In vitro study | Tassi slam inhibits the proliferation of human leukemia and lymphoma cells with an ED50 of 7 to 40 μm. LY573636 was also able to induce apoptosis in HL60,Reh, and MD901 cell lines, mainly through reduction of mitochondrial membrane potential and induction of reactive oxygen species. In addition, Tasisulam was also able to produce anti-malignant cell proliferation effects in more than 120 of the 70% cell lines, with an EC50 of less than 50 μm. Tasisulam can cause phase Calu-6 arrest and subsequent apoptosis in A- 375 and G2-M cells. In vitro experiments, Tasisulam was able to inhibit the formation of endothelium-like structures induced by VEGF, FGF and EGF with EC50 of 47,103, and 34 nM, respectively. |
In vivo study | Tassi slam causes morphological features of vascular normalization, including an increase in adventitial cell coverage in vivo and a decrease in tissue hypoxia. Tassulam in a Calu-6 non-small cell lung cancer xenograft model (25 or 50mg/kg, I. v.) exhibits dose-dependent antitumor activity, induces apoptosis, normalizes tumor-associated blood vessels. In addition, Tasisulam exhibited potent anti-tumor activity against a range of in vivo xenografts, including colorectal cancer (HCT-116), melanoma (A-375), gastric cancer (NUGC-3), blood cancer (MV-4-11). And pancreatic cancer (QGP-1). |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.409 ml | 12.045 ml | 24.09 ml |
5 mM | 0.482 ml | 2.409 ml | 4.818 ml |
10 mM | 0.241 ml | 1.205 ml | 2.409 ml |
5 mM | 0.048 ml | 0.241 ml | 0.482 ml |